Advertisement
Canada markets close in 1 hour 34 minutes
  • S&P/TSX

    21,547.04
    -5.31 (-0.02%)
     
  • S&P 500

    5,136.08
    -1.00 (-0.02%)
     
  • DOW

    38,997.68
    -89.70 (-0.23%)
     
  • CAD/USD

    0.7364
    -0.0015 (-0.20%)
     
  • CRUDE OIL

    78.63
    -1.34 (-1.68%)
     
  • Bitcoin CAD

    90,764.87
    +5,538.06 (+6.50%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,123.00
    +27.30 (+1.30%)
     
  • RUSSELL 2000

    2,082.23
    +5.84 (+0.28%)
     
  • 10-Yr Bond

    4.2230
    +0.0430 (+1.03%)
     
  • NASDAQ

    16,243.75
    -31.19 (-0.19%)
     
  • VOLATILITY

    13.39
    +0.28 (+2.14%)
     
  • FTSE

    7,640.33
    -42.17 (-0.55%)
     
  • NIKKEI 225

    40,109.23
    +198.43 (+0.50%)
     
  • CAD/EUR

    0.6780
    -0.0022 (-0.32%)
     

12 Stocks Billionaire Steve Cohen Just Bought and Sold

In this article, we're going to take a look at 12 stocks billionaire Steve Cohen just bought and sold. To jump ahead to see the top picks that made our list, follow this link to read about the 5 Stocks Billionaire Steve Cohen just Bought and Sold.

Billionaire Steve Cohen is one of the most renowned hedge fund managers on the Street. In 1992, Cohen launched S.A.C Capital Advisors and grew its Assets Under Management from $25 million to mode than $16 billion in 2008. At one point SAC employed around 800 people. The fund's growth was spurred by Cohen and his team's investment acumen. SAC Capital Advisors was one of the best performing hedge funds, managing at one point to net 70% in annual returns two years in a row. Historically, between 1992 and 2013, SAC Capital's average annual returns amounted to 30%, outperforming many other hedge funds and the market.

However, things turned to worse when in 2010, the Securities and Exchange Commission opened an investigation into SAC on insider trading allegations and several employees were indicted on insider trading charges. In 2013, the firm pleaded guilty to insider trading charges and paid more than $1.0 billion in penalties. A year later, several former employees of SAC were convicted, one of whom, Mathew Martoma was accused of running one of the largest insider transactions in history, which allegedly generated $276 million in profit. As part of a separate lawsuit in 2016, Cohen was prohibited from managing money for outside investors for two years.

In 2014, Cohen established Point72 Asset Management as a family office to manage his own capital. In 2018, two years after Cohen's ban and the shutdown of SAC Capital Advisors, Point72 became a hedge fund that started to accept outside investors' money. Currently, Point72 has more than $31 billion in Assets Under Management and employs more than 2,800 people, according to its website. The firm has seven offices in the US, four locations in Europe and Middle East, and five in the Asia-Pacific region. In 2022, Point72 generated a return of 10.3%, earning its investors around $2.40 billion, according to Financial Times.

Stocks to Sell in 2023 According to Billionaire Steve Cohen
Stocks to Sell in 2023 According to Billionaire Steve Cohen

Steven Cohen in addition to making a fortune estimated at almost $20 billion is also known for his rather lavish art collection. One of the exhibits in this collection is a 14-foot shark preserved in formaldehyde, designed by Damien Hirst and titled "The Physical Impossibility of Death in the Mind of Someone Living". In 2004, Cohen purchased this artwork for $8 million. Cohen's collection also includes or included paintings by Picasso, artwork by Andy Warhol, and others. Cohen also has several hundred millions worth of real estate in New York, Connecticut and California. In 2020, Cohen also purchased New York Mets baseball team for $2.4 billion and is currently in profit as the team's value is currently estimated at $2.9 billion.

Now, we cannot talk about the stocks that Steve Cohen just bought and sold without going through Point72 Asset Management's latest 13F filing. At the end of the third quarter, Point72 had an equity portfolio worth over $34 billion, which was highly diversified and included over 2,400 positions. During the period, the investor closed 600 positions and acquired more than 900 new holdings. Among the sectors the fund is focused the most on are Technology, Healthcare and Consumer Discretionary.

From the technology sector, Cohen personally seems to be fond of Artificial Intelligence businesses as he mentioned during a private conference event. That's probably one of the reasons why Point72's largest long position is represented by NVIDIA Corporation (NASDAQ:NVDA), followed by Microsoft Corporation (NASDAQ:MSFT), and Amazon.com, Inc. (NASDAQ:AMZN). In all three companies, Point72 increased its position during the third quarter. The fund added 2,700 shares to its position in NVIDIA Corporation (NASDAQ:NVDA) and raised its stakes in Microsoft Corporation (NASDAQ:MSFT) and Amazon.com, Inc. (NASDAQ:AMZN) by 11% and 39%, respectively. NVIDIA Corporation (NASDAQ:NVDA), Microsoft Corporation (NASDAQ:MSFT) and Amazon.com, Inc. (NASDAQ:AMZN) stand to benefit a lot from the ascension of AI and are among the 5 best artificial intelligence stocks to buy according to hedge funds.

Our Methodology

To identify which companies to include in our list of 12 stocks billionaire Steve Cohen just bought and sold we looked through Cohen's latest and previous 13F filing and identified which companies were added to the portfolio during the third quarter, but also in which businesses the billionaire's fund liquidated its position. We then calculated the value of these positions based on the closing price on the last day of the quarter and ranked the picks in a decreasing order of this metric..

12. Dynatrace Inc (NYSE:DT)

Value of Position: $69.65 million

Bought or Sold: Bought

Dynatrace Inc (NYSE:DT)

During the third quarter, Point72 Asset Management acquired 1.49 million shares of Dynatrace Inc (NYSE:DT), the stake being valued at roughly $69.65 million. Dynatrace Inc (NYSE:DT) provides a software observability platform that uses AI as the underlying technology. The company's stock has appreciated by 35% since the beginning of the year amid the company beating the estimates on both top and bottom-lines for the past three fiscal quarters. For the latest quarter, Dynatrace reported EPS of $0.31 and revenue of $351.70 million, vs expectations of $0.24 and $345 million, respectively. During Dynatrace, Inc. (NYSE:DT) Q2 2024 earnings call, the company's CFO Jim Benson said that the company was raising its revenue guidance to between $1.41 billion and $1.42 billion, which would represent a growth between 21% and 22%.

Besides Steve Cohen's Point72 Asset Management, two other investors bullish on Dynatrace Inc (NYSE:DT) are Robert G. Moses' RGM Capital and Panayotis Takis Sparaggis' Alkeon Capital Management, which upped their stakes by 10% and 47% during the third quarter and currently own 3.52 million shares, and 1.89 million shares, respectively.

11. Ovintiv Inc (NYSE:OVV)

Value of Position: $97.64 million

Bought or Sold: Bought

Ovintiv Inc (NYSE:OVV) is another new addition to Point72's equity portfolio with Steven Cohen's hedge fund reporting the addition of 2.05 million shares valued at $97.64 million. An independent petroleum company, Ovintiv Inc (NYSE:OVV) reported a total production of 572,000 barrels of oil equivalent per day for the third quarter and 1.63 million cubic feed of natural gas per day. The company also reported net earnings of $1.47 per share and posted a dividend of $0.30 per share for the third quarter. In addition, Ovintiv Inc (NYSE:OVV) provided its full-year production guidance of 550 to 560 million barrels of oil equivalent per day and a full-year capital investment between $2.75 billion and $2.79 billion.

Ken Griffin's Citadel Investment Group is also bullish on Ovintiv Inc (NYSE:OVV), the company representing one of the hedge fund's biggest energy stock picks. Overall, there were 31 investors in our database bullish on Ovintiv Inc (NYSE:OVV), up from 24 funds a quarter earlier.

10. argenx SE - ADR (NASDAQ:ARGX)

Value of Position: $123.16 million

Bought or Sold: Bought

argenx SE - ADR (NASDAQ:ARGX) is a Netherlands-based global immunology company, which focuses on developing novel antibody-based medicines aimed at helping people with autoimmune diseases. Earlier this month, the company said that it had received the approval from the European Commission for subcutaneous injectable VYVGART as an addition to the standard therapy for the treatment of generalized myasthenia gravis. Since the beginning of the year, argenx SE - ADR (NASDAQ:ARGX)'s stock surged by more than 31%, mainly due to a spike in July on the back of the company reporting positive topline data from its study on a therapy for chronic inflammatory demyelinating polyneuropathy.

During the third quarter, Point72 Asset Management initiated a stake in argenx SE - ADR (NASDAQ:ARGX), by adding 250,500 shares worth $123.16 million. Billionaire Steve Cohen's fund joined 47 other hedge funds bullish on the company as of the end of September.

9. Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)

Value of Position: $125.66 million

Bought or Sold: Bought

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) saw a significant increase in popularity during the third quarter, as the number of investors tracked by Insider Monkey bullish on the company surged to 38 from 21 and the aggregate value of their holdings appreciated to $670.11 million from $303.60 million. Steve Cohen's fund also added 4.23 million shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) to its equity portfolio.+

In September, Crinetics Pharmaceuticals' stock saw a spike of more than 90% on the back of the company announcing positive phase 3 trial results for its oral therapy for acromegaly, a rare condition that causes pituitary gland to secrete excess growth hormone. Currently this condition can only be treated through surgery or monthly injections of a certain drug. Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) has another drug candidate in trial for the treatment of Cushing's disease and congenital adrenal hyperplasia with data from these studies expected in the second half of 2024.

8. Macy's Inc (NYSE:M)

Value of Position: $125.93 million

Bought or Sold: Sold

During the third quarter Point72 Asset Management liquidated its stake in Macy's Inc (NYSE:M), previously having reported ownership of 10.85 million  shares. The fund first initiated a stake in the department store operator back in 2021. Macy's Inc (NYSE:M) is down by 36% over the last year. Macy's Inc (NYSE:M) reported a year-on-year revenue decline for the past four quarters as the company has been facing major headwinds and the whole department store and mall segment has been struggling over the COVID-19 pandemic. For the full 2023, the company expects revenue between $22.9 million and $23.2 billion and comparable sales decline between 7% and 6%, a slight improvement from the previous guidance. "Our sales outlook reflects our confidence in Macy’s, Inc. as a gift-giving destination, including the expected increase in beauty sales penetration, particularly fragrances," Macy's Inc (NYSE:M)'s CFO and COO Adrian Mitchell said during the earnings call.

There were 32 funds in our database long Macy's Inc (NYSE:M) at the end of September, holding in aggregate $357.80 million worth of shares. Among these, Peter Rathjens, Bruce Clarke and John Campbell's Arrowstreet Capital is the top shareholder with a $131.43 million position.

7. Hologic, Inc. (NASDAQ:HOLX)

Value of Position: $132.03 million

Bought or Sold: Bought

Our list of stocks billionaire Steve Cohen just bought and sold continues with Hologic, Inc. (NASDAQ:HOLX), in which Point72 Asset Management initiated a stake by buying 1.90 million shares. In total, there were 44 funds followed by Insider Monkey bullish on Hologic, Inc. (NASDAQ:HOLX) at the end of September, up by two over the quarter.

Hologic, Inc. (NASDAQ:HOLX) is a healthcare technology company that sells devices for diagnostics, surgery and imaging aimed primarily at women's health. In 2013 the company was targeted by activist investor Carl Icahn, earning a spot in our list of long-term returns of Carl Icahn's 40 activist targets. In the fiscal fourth quarter, Hologic, Inc. (NASDAQ:HOLX) recorded EPS of $0.89, topping the expectations of $0.84 and revenue of $945.30 million was $5.39 million higher than the consensus estimate.

6. ImmunoGen, Inc. (NASDAQ:IMGN)

Value of Position: $138.26 million

Bought or Sold: Sold

ImmunoGen, Inc. (NASDAQ:IMGN) is another company in which Point72 liquidated its position during the third quarter, having previously owned 8.71 million shares. In May, shares of ImmunoGen, Inc. (NASDAQ:IMGN) spiked after the company reported positive late-stage trial results for its experimental ovarian cancer drug Elahere. The company said the drug helped extend the time the patient lived without the cancer worsening compared to chemotherapy. Interestingly, Point72 Asset Management initiated a stake in ImmunoGen, Inc. (NASDAQ:IMGN) during the second quarter of 2023. For the third quarter, ImmunoGen, Inc. (NASDAQ:IMGN) reported revenue of $113.4 million, including $105.2 million from sales of Elahere, versus revenue of $15.4 million posted for the same period of the last year.

There were 46 hedge funds in our database bullish on ImmunoGen, Inc. (NASDAQ:IMGN) at the end of September, up from 42 funds a quarter earlier.

Click to continue reading and see 5 Stocks Billionaire Steve Cohen Just Bought and Sold. Suggested articles: Billionaire Steven Cohen’s Top High Dividend Stock Picks 10 Stocks Billionaire Leon Cooperman Just Bought and Sold 11 Most Undervalued Utility Stocks to Buy According to Hedge Funds